Manager/Senior Manager, Clinical Finance Business Partner
Systimmune
Manager/Senior Manager, Clinical Finance Business Partner
Systimmune
Develops bispecific antibodies and ADCs
SystImmune is a leading and well-funded clinical-stage biopharmaceutical company located in Bothell, WA and Princeton, NJ. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development. We offer an opportunity for you to learn and grow while making significant contributions to the company’s success.
The Manager or Senior Manager, Clinical Finance Business Partner will lead the financial planning and analysis efforts for the clinical portfolio of the company. This strategic role is responsible for developing and overseeing financial models, budgets, and forecasts that support our clinical development objectives. This role will also be responsible for managing finance-related issues with external alliance partners. The Clinical Finance Business Partner will collaborate with cross-functional teams to ensure financial alignment with clinical timelines and corporate goals, ultimately driving informed decision-making and resource allocation.
This position requires a full-time onsite presence in Bothell, WA.
Responsibilities:
Develops bispecific antibodies and ADCs
Systimmune is a biopharmaceutical company that develops antibody-based cancer therapies, including bispecific and trispecific antibodies and antibody-drug conjugates (ADCs). These products are designed to act on the solid tumor micro-environment to directly attack tumors and/or to activate the immune system to fight cancer. The company uses multiple immuno-oncology platforms and experienced scientists to create biologics that intervene in the tumor environment in systematic ways. Compared with competitors, Systimmune emphasizes integrating several antibody-based modalities (bispecifics, trispecifics, and ADCs) and a deep focus on the solid tumor micro-environment, aiming to translate biological insight into targeted, immune-engaging therapies. The goal is to produce biologics that effectively modulate the tumor environment and mobilize the body's own immune response to destroy cancer cells.
Explore more opportunities at Systimmune